Fig. 2: In vivo-launched 2196- and 2130-based DMAbs retain activity against major SARS-CoV-2 viral variants. | Nature Communications

Fig. 2: In vivo-launched 2196- and 2130-based DMAbs retain activity against major SARS-CoV-2 viral variants.

From: DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2

Fig. 2

Neutralizing activity of sera samples (independent biological replicates) from DMAb-administered mice (n = 3–5/group, as indicated) against a USA-WA1/2020 SARS-CoV-2 pseudovirus. Graphs depict neutralization curves for each sera sample (best-fit lines and individual data points derived from technical replicates). b–e Corresponding activity of these sera against the indicated variant pseudoviruses. Graphs depict matched ID50s values of each sample against the indicated VoCs compared to USA-WA1/2020. Average fold change (x) in ID50 for each group is indicated for the following SARS-CoV-2 variants: b B.1.1.7; c B.1.351; d B.1.526; e B.1.617.2. f Comparison of serum ID50 values for individual samples against USA-WA1/2020 (group GM± GSD indicated). Differences between groups were measured using Kruskal–Wallis test followed by Dunn’s post hoc analysis. P values indicated. g Comparison of calculated IC50 values for individual samples against USA-WA1/2020 (group mean ± SD indicated). Differences between groups were measured using Kruskal–Wallis test followed by Dunn’s post hoc analysis. P values indicated. Data reproduced in >2 independent experiments with similar results. Source data are provided as a Source Data file.

Back to article page